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INTRODUCTION
Meta-analysis has shown that amiodarone treatment
significantly inhibits ventricular arrhythmias in cases
of post-acute myocardial infarction and chronic heart
failure(1-5). Amiodarone decreases arrhythmic death
caused by non-ischemic heart failure, thereby improv-
ing the total mortality rate. Furthermore, thisdrugmay
be able to control ventricular arrhythmia during the
electrically unstable stage caused by acutemyocardial
infarction (1-5).
However, amiodarone does not control all lethal ven-
tricular arrhythmias, and it does not improve progno-
sis unlike the case with the implantable cardioverter
defibrillator. Therefore, the application of both amio-
darone and an implantable cardioverter defibrillator
should be considered in patients whose cardiac dys-
function causes sustained ventricular arrhythmias (6).
If the mechanism underlying amiodarone’s suppres-
sion of ventricular tachycardias is easily identified, it
might be possible to delay implanting the cardioverter
defibrillator. In the present study, we report that a pa-
tient could be identified as a responder or nonresponder
to amiodarone treatment for ventricular tachycardia
by using signal-averaged electrocardiogram (SAECG).
We also found that ventricular tachycardiawas suppressed
by amiodaron.
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Abstract : A75-year-old man suffered sustained ventricular tachycardia with syncopal attack.
Ventricular tachycardias appeared repeatedly, and an electrical defibrillator was used after
an anti-arrhythmic drug, such as lidocaine or mexiletine, proved ineffective. The tachycardias
had multipleorigins, and thesignal-averaged electrocardiogram(SAECG)showedventricularlate
potential before the administration of amiodarone. After administration, the filtered QRS
and duration of the late potential increased, but therecurrenceof tachycardias was suppressed.
The reason for this is thought to be that amiodarone blocked the sodium channel and delayed
conduction, consequently blocking reentry, because amiodaron has antiarrhymic properties
with a prolongation of refractoriness and minimal effect on conduction velocity in ventricular
myocardium, and inhibits sympathetic activity, and blocks L-type calcium channel besides
the depression of the fast sodium channel. In this case, SAECG predicted to some degree
whether or not this patient’s ventricular tachycardia would respond to amiodarone.
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CASE REPORT
A75-year-old man was referred to the Tokushima
University Hospital because of a syncopal attack. The
patient, whose family had no history of sudden cardiac
death, had noted a previous syncopal attackonOctober
10, 2003, during a walk, and was transported to the
nearest emergency hospital. There, ventricular tachy-
cardia was recognized and, after an anti-arrhythmic
drug (sodium channel blocker, such as lidocaine or
mexiletine) proved ineffective, an electrical defibrillator
was used to obtain a normal sinus rhythm. Thereafter
the patient experienced repeated ventricular tachy-
cardias. After 7 days at the emergency hospital, he
was referred to our cardiovascular department for
further examination.
At his physical examination, the patient’s pulse was
54/minute and regular, and his blood pressure was
120/60 mmHg. In auscultation, no heartmurmurswere
heard and breathing sounds were normal. His abdo-
men was flat and soft, and his liver and spleen were
not palpable. No edema was found in the lower limbs.
Except for the increase in brain natriuretic peptide
(BNP, 486pg/dl), there were no abnormalities in the
patient’s blood biochemical data, whichwereas follows :
leukocyte count 4800/µl, erythrocyte count 486×104/
µl, hemoglobin 13.4g/dl, hematocrit 42.7%, platelet
count 20.8×104/µl, glutamic oxaloacetic transaminase
(GOT) 45U/L, glutamic pyruvic transaminase (GPT)
39 U/L, lactate dehydrogenase 250U/L, alkaline phos-
phatase 244U/L, gamma-glutamyl transferase 34U/L,
creatine kinase 85U/L, total bilirubin 0.5mg/dl, total
protein 6.9mg/dl, total cholesterol 147mg/dl, triglyc-
eride 176 mg/dl, HDL-cholesterol 29mg/dl, blood
urea nitrogen 12mg/dl, creatinine1.22mg/dl, Na 142
mEq/L, K 4.5mEq/L, Cl 104mEq/L, C-reactive protein
0.06 mg/dl.
The patient’s electrocardiogram (ECG) taken at
admission to our department is shown in Figure 1.
Negative P-waves appeared in leads Ⅱ,Ⅲ, and and
aVF, and the QRS axis showed left-axis deviation and
a deep S-wave appeared in lead V6. In chest X-ray
(Figure 2), the cardiothoratic ratio was 61%, demon-
strating cardiomegaly. However, there were no find-
ings of pulmonary congestion.
A standard 12-lead ECG during a sustained ven-
tricular tachycardia is shown in Figure 3. The patient’s
heart rate was 255/minute, and QRS showed left-axis
deviation and right bundle branch block. The echo-
cardiogram in the sinus rhythm demonstrated that
the left ventricular endo-diastolic dimension (LVDd)
was 5.8cm, the left ventricular endo-systolic dimension
(LVDs) was 3.9cm, the thickness of the interventricular
septum was 24.9mm, the posterior wall of the left ven-
tricle was 11.4 mm, fractional shortening was 33%,
and the ejection fraction of the left ventricle was 57% ;
in addition, hypertrophic cardiomyopathy (asymmetric
septal hypertrophy) was recognized. In the coronary
angiography, no significant stenosis was seen in either
the left or the right coronary artery.
Figure 1 Patient’s electrocardiogram at admission.
Figure 2 Chest X-ray at admission.
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Figure 4 shows body surfacemaps
of two types of ventricular extrasys-
tole. Thesemapswere recordedduring
a clinical spontaneous attack using
a multi-purpose electrocardiograph
(VCM-3000, FukudaDenshi Co., Ltd.,
Tokyo, Japan). In Figure 4a, themini-
mum was located at the G-5 lead and
maximal at the D-4 lead. The origin
of the ventricular arrhythmiawas pre-
dicted to be the anterior wall of the left
ventricle to themid-baseof the septum.
In Figure4b, the lateral base of the
left ventricle was the site of origin of
the ventricular arrhythmia because
the minimum was located at the I-5
lead and the maximum at the F-3 lead.
SAECGwas recordedusingaVCM-
8000 electrocardiograph(FukudaDenshi
Co., Ltd., Tokyo, Japan). Using the
vector magnitudemethod reportedby
Simson et al.(7), signals obtained by
bipolar leads corresponding to the
three axes of the X, Y, and Z leads of
Frank leads were averaged to obtain
values for (X2＋Y2＋Z2)1/2. Signals from
256 heartbeats were averaged using
a high-cut filter (300 Hz) and a low-
cut filter(40 Hz). Three parameters
were measured : 1) the filtered-QRS
(f-QRS) duration (in milliseconds),
Figure 3 Standard 12-lead ECG during sustained ventricular tachycardia.
Figure 4 Body surface maps 10, 20, 30, and 40msec after the onset of QRS waves
on two types of ventricular extrasystole.
Left half of frame is the chest (horizontal axis ;A-I) and right half (horizontal axis ;
I-M) is the back. Gray area is negative potential, white area is negative and ＋, －
denote the maximum (Max) and minimum (Min) respectively. Lines represent
the isopotential line increments.
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2)the root mean square (RMS) voltage (in microvolts)
of the terminal 40 msec of the f-QRS waveform (RMS-
40), and 3)the last duration (in millisecond) of the
terminal f-QRS waveform within 40µV (LAS40). The
late potential were defined to be present if the SAECG
showed at least the two items of the following criteria :
f-QRS＞130 msec, RMS40＜15µV, or LAS40＞40msec.
Figure 5 shows SAECG before (panel a) and two
weeks after (panel b) administration of amiodarone.
The f-QRS, LAS40, and RMS40 parameters of SAECG
before and after administration of amiodarone were
181msec and204msec, 95msec and143msec, and
6.9µV and 6.3 µV, respectively. In the present case,
the late potentials before and after administration of
amiodarone were positive. Table 1 shows the percent
changes of the three SAECGparameters in this patient.
The percent changes of f-QRS, LAS40, and RMS40
were＋12.7%,＋50.1% and -8.7%, respectively, from before
to after the administration of amiodarone.
The electrophysiological study revealed two types
of sustained ventricular tachycardia:the right bundle
branch block type with left-axis deviation, and the left
bundle branch block type with a normal axis (Figure
6). Catheter ablation was not performed because of
the multiple origins of the ventricular tachycardias.
After the administration of amiodarone for 2 weeks,
an electrophysiological study was performed again.
Amiodarone was thought to prevent ventricular tachy-
cardias from appearing after the coupled stimulation
at the right ventricular apex. Figure 7 shows the clinical
course of this patient. The frequency of ventricular
tachycardia in the short run decreased and finally the
episode disappeared. Oral amiodarone was started out
at 400 mg/day for 3 days and thereafter was continued
at 100 mg/day. By the patient’s 10th day at our hos-
pital, ventricular tachycardia was no longer recognized.
Although amiodarone eliminated ventricular tachy-
cardia in this patient, a cardioverter defibrillator was
implanted as a backup because the patient had symp-
toms of a syncopal attack. The patient is now being
followed up at an outpatient department. His ventricular
tachycardia has thus far been suppressedwithout the
operation of the defibrillator.
Table 1. Percent change of three parameters of SAECG
Before administration of amiodarone After administration of amiodarone percent change of parameter
f-QRS
LAS40
RMS40
181 msec
95 msec
6.9 µV
204 msec
143 msec
6.3 µV
＋12.7%
＋50.1%
‐8.7%
f-QRS, filter-QRS duration;LAS 40, duration over the last 40msec under the 40µV duration ; RMS 40, root mean square voltage
of the terminal 40 msec of the f-QRS waveform.
Figure 5 SAECG before (panel a) and after (panel b) administration of amiodarone.
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DISCUSSION
Brembilla-Perrot et al.(8) reported that SAECG
was useful for distinguishing responders from non-
responders to amiodarone for treatment of ventricular
tachycardia. They did not explain why the increased
filtered QRS duration and the prolonged late ventricular
potential indicated the effectiveness of anti-arrhythmic
action. In agreement with their study, amiodarone
controlled ventricular tachycardia in our patient, since
the three parameters of SAECG showmarked change
from before to after administration of amiodarone.
These findings indicate that this patient is a responder
to amiodarone. Amiodarone has a sodium channel-
blocking effect in addition to its potassium channel-
blocking effect. The SAECG ismore sensitive than the
standard ECG in detecting changes in QRS duration
resulting from the slowing down of conduction by
amiodarone.
The relationship between the ventricular late potential
in SAECG and ventricular tachycardias has reported
a number of times (9-11). A high possibility of occur-
rence of ventricular tachycardias has been reported
in cases where ventricular late potential is positive;
conversely, the possibility of ventricular tachycardia
is low in cases where the ventricular delay potential
is negative (12).
Late ventricular potential appears in damagedmyo-
cardium due to myocardial infarction or cardiomyopa-
thy. This delayed potential reflects a conduction dis-
turbance that creates a reentry circuit. This reentry
circuit is thought to be the cause of reentrant ven-
tricular arrhythmia. Moreover, hypertrophic cardio-
myopathy is related to sudden death caused by ven-
tricular arrhythmias, although it was reported that
ventricular hypertrophy has a relatively good prognosis
(13,14). This suggested that a slow conduction caused
ventricular tachycardia in hypertrophic myocardium
with strong degeneration.
Fauchier et al. (15) reported the positive rates of
a ventricular late potential are 5-20% and 1-5% in hy-
pertrophic cardiomyopathy and hypertensive cardi-
omyopathy, respectively. Furthermore, it has been
reported that ventricular late potential is frequently
seen in caseswith left ventricular dysfunction, although
it has also been reported that ventricular late poten-
tial and cardiac function are independent of each other
(16).
In the present case, no obvious abnormalities of
cardiac function appeared, despite the ventricular late
potential. This suggested that a conduction delay exists
in hypertrophic myocardiumwith strong degeneration.
In our patient, ventricular late potential still existed
after the administration of amiodarone. Instead, ven-
Figure 6 Electrophysiological study of this case.
Two types of suspended ventricular tachycardia are induced.
Figure 7 Clinical course of this patient.
EPS, Electrophysiological study ; NSVT, non-sustained ventricular
tachycardia
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tricular tachycardia was suppressed after the admini-
stration. Prolongation of QRS and of the late potential
duration by other sodium channel-blocking drugs
correlates with prolongation of the ventricular tachy-
cardia cycle length (17). Therefore, it is suggested that
in patients with longer filtered QRS and late potential,
amiodarone causes a greater conduction delay and
suppresses reentrant tachycardias. Amiodarone sup-
presses conduction in morbid myocardium more
than it does in normal myocardium. Amiodarone
completely inhibits the conduction disturbance of
hypertrophic lesions. Therefore, the three parameters
of SAECGmight have been worse than they actually
were. The percent changes of f-QRS and LAS40 were
increased, and RMS40 were deceased after the ad-
ministration of amiodarone.
Furthermore, the occurrence of tachyarrhythmias
greatly influences the prognosis and strategy ofmedical
treatment. In order to treat ventricular tachycardias
in patients with heart failure, a drugwith little influence
on cardiac function is required. To prevent sudden
arrhythmic cardiac death, an implantable cardioverter
defibrillator has been introduced in addition to amio-
darone treatment, to improve the prognosis of ven-
tricular tachycardia (18).
The present case was diagnosed as a non-obstructive
hypertrophic cardiomyopathy. Even though heart
failure was not recognized, medical treatment with
an anti-arrhythmic drug (sodium channel blocker) was
not effective. Because syncopal attack occurred in this
case, amiodarone administration and the implantation
of a cardioverter defibrillator were both necessary to
prevent sudden cardiac death.
It is dangerous to prescribe amiodarone aimlessly,
since its side effects including interstitial pneumonia
(19), hypofunction of the thyroid gland (20), and liver
injury (21). Therefore, it is necessary to stop amiodar-
one treatment at an early stage if an anti-arrhythmic
effect does not appear imminent. In the present case,
we were able to identify the effect of amiodarone by
examining the SAECG parameters.
Even though responders to amiodarone can be iden-
tified with SAECG, this will not reduce the indication
for an implantable cardioverter defibrillator. That is
because in organic heart disease, ventricular tachy-
cardia is caused by the interaction of many factors,
such as an anatomical barrier by the cardiac tissue,
a conduction delay in abnormal myocardium, and an
increase in endogenous catecholamines followed by
cardiac dysfunction. Since the implantable cardioverter
defibrillator decreases the likelihoodof suddencardiac
death and improves the prognosis in cases with fatal
arrhythmia, it may be the first choice of treatment for
patients with ventricular tachycardia with cardiac dys-
function. However, the implantation of a cardioverter
defibrillator remarkably reduces the patient’s quality
of life. Therefore, this approach needs to be combined
with drug treatment, such as that with amiodarone,
or catheter and/or surgical ablation. In the present
case, we combined an implantable cardioverter de-
fibrillator with amiodarone treatment, and the patient
is doing well.
CONCLUSIONS
We experienced a patient with sustained ventricular
tachycardia. Amiodarone was effective in maintaining
sinus rhythm. Our results suggested that the effective-
ness of amiodarone can be predicted by examining
the parameters of SAECG.
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